Skip to main content
Hit enter to search or ESC to close
Close Search
Menu
About
Company
Leadership
Careers
Platform
Platform Overview
DELIVER Platform
Cargo Platform
Pipeline
Development Programs
Duchenne Muscular Dystrophy (DMD)
Facioscapulohumeral Dystrophy (FSHD)
Publications
Newsroom
Careers
Contact
linkedin
Presentation
Developing a potent gene therapy candidate for facioscapulohumeral muscular dystrophy (FSHD) through high throughput AAV capsid and cargo engineering
By
Kate Therapeutics
May 9, 2024
No Comments
KateTx FSHS poster_ASGCT 2024_v7
Share
Share
Share
Pin
Close Menu
About
Company
Leadership
Careers
Platform
Platform Overview
DELIVER Platform
Cargo Platform
Pipeline
Development Programs
Duchenne Muscular Dystrophy (DMD)
Facioscapulohumeral Dystrophy (FSHD)
Publications
Newsroom
Careers
Contact